<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33174532</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1754-8411</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>30</Day></PubDate></JournalIssue><Title>Disease models &amp; mechanisms</Title><ISOAbbreviation>Dis Model Mech</ISOAbbreviation></Journal><ArticleTitle>Chronic administration of P2X7 receptor antagonist JNJ-47965567 delays disease onset and progression, and improves motor performance in ALS SOD1<sup>G93A</sup> female mice.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">dmm045732</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1242/dmm.045732</ELocationID><Abstract><AbstractText>Neuroinflammation is one of the main physiopathological mechanisms of amyotrophic lateral sclerosis (ALS), produced by the chronic activation of microglia in the CNS. This process is triggered by the persistent activation of the ATP-gated P2X7 receptor (P2RX7, hereafter referred to as P2X7R). The present study aimed to evaluate the effects of the chronic treatment with the P2X7R antagonist JNJ-47965567 in the development and progression of ALS in the SOD1<sup>G93A</sup> murine model. SOD1<sup>G93A</sup> mice were intraperitoneally (i.p.) injected with either 30&#x2005;mg/kg of JNJ-47965567 or vehicle 4 times per week, from pre-onset age (here, postnatal day 60; P60) until study endpoint. Body weight, motor coordination, phenotypic score, disease onset and survival were measured throughout the study, and compared between vehicle- and drug-injected groups. Treatment with the P2X7R antagonist JNJ-47965567 delayed disease onset, reduced body weight loss and improved motor coordination and phenotypic score in female SOD1<sup>G93A</sup> mice, although it did not increase lifespan. Interestingly, neither beneficial nor detrimental effects were observed in males in any of the analyzed parameters. Treatment did not affect motor neuron survival or ChAT, Iba-1 and P2X7R protein expression in endpoint individuals of mixed sexes. Overall, chronic administration of JNJ-47965567 for 4 times per week to SOD1<sup>G93A</sup> mice from pre-onset stage altered disease progression in female individuals while it did not have any effect in males. Our results suggest a partial, yet important, effect of P2X7R in the development and progression of ALS.</AbstractText><CopyrightInformation>&#xa9; 2020. Published by The Company of Biologists Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ruiz-Ruiz</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-5990-4862</Identifier><AffiliationInfo><Affiliation>Instituto Te&#xf3;filo Hernando, Facultad de Medicina, Universidad Aut&#xf3;noma de Madrid, Madrid 28029, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Farmacolog&#xed;a, Facultad de Medicina, Universidad Aut&#xf3;noma de Madrid, Madrid 28029, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Magro</LastName><ForeName>Nuria</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-5896-9258</Identifier><AffiliationInfo><Affiliation>Departamento de Anatom&#xed;a, Histolog&#xed;a y Neurociencia, Facultad de Medicina, Universidad Aut&#xf3;noma de Madrid, Madrid 28029, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Negredo</LastName><ForeName>Pilar</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-7274-5579</Identifier><AffiliationInfo><Affiliation>Departamento de Anatom&#xed;a, Histolog&#xed;a y Neurociencia, Facultad de Medicina, Universidad Aut&#xf3;noma de Madrid, Madrid 28029, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avenda&#xf1;o</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-8871-2488</Identifier><AffiliationInfo><Affiliation>Departamento de Anatom&#xed;a, Histolog&#xed;a y Neurociencia, Facultad de Medicina, Universidad Aut&#xf3;noma de Madrid, Madrid 28029, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhattacharya</LastName><ForeName>Anindya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuroscience Therapeutic Area, Janssen Research and Development LLC., 3210 Merryfield Row, San Diego, CA 92121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceusters</LastName><ForeName>Marc</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9906-065X</Identifier><AffiliationInfo><Affiliation>Neuroscience Therapeutic Area, Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Beerse B-2340, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a</LastName><ForeName>Antonio G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0002-6517-3565</Identifier><AffiliationInfo><Affiliation>Instituto Te&#xf3;filo Hernando, Facultad de Medicina, Universidad Aut&#xf3;noma de Madrid, Madrid 28029, Spain agg@uam.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Farmacolog&#xed;a, Facultad de Medicina, Universidad Aut&#xf3;noma de Madrid, Madrid 28029, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria, Hospital Universitario de La Princesa, Madrid 28006, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Dis Model Mech</MedlineTA><NlmUniqueID>101483332</NlmUniqueID><ISSNLinking>1754-8403</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000590736">JNJ-47965567</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058920">Purinergic P2X Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058486">Receptors, Purinergic P2X7</NameOfSubstance></Chemical><Chemical><RegistryNumber>25X51I8RD4</RegistryNumber><NameOfSubstance UI="D009536">Niacinamide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023381" MajorTopicYN="N">Endpoint Determination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="Y">Motor Activity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009536" MajorTopicYN="N">Niacinamide</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058920" MajorTopicYN="N">Purinergic P2X Receptor Antagonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058486" MajorTopicYN="N">Receptors, Purinergic P2X7</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045442" MajorTopicYN="N">Rotarod Performance Test</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015431" MajorTopicYN="N">Weight Loss</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Neuroinflammation</Keyword><Keyword MajorTopicYN="N">P2X7 receptor</Keyword><Keyword MajorTopicYN="N">Purinergic signaling</Keyword><Keyword MajorTopicYN="N">SOD1G93A mice</Keyword></KeywordList><CoiStatement>Competing interestsThe authors of this article have no competing interests to declare. A.B. and M.C. are full-time employees of Janssen Research and Development.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>11</Day><Hour>8</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33174532</ArticleId><ArticleId IdType="pmc">PMC7648608</ArticleId><ArticleId IdType="doi">10.1242/dmm.045732</ArticleId><ArticleId IdType="pii">13/10/dmm045732</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Apolloni S., Amadio S., Montilli C., Volonte C. and D'ambrosi N. (2013a). Ablation of P2X7 receptor exacerbates gliosis and motoneuron death in the SOD1-G93A mouse model of amyotrophic lateral sclerosis. Hum. Mol. Genet. 22, 4102-4116. 10.1093/hmg/ddt259</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt259</ArticleId><ArticleId IdType="pubmed">23736299</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S., Parisi C., Pesaresi M. G., Rossi S., Carr&#xec; M. T., Cozzolino M., Volont&#xe9; C. and D'Ambrosi N. (2013b). The NADPH oxidase pathway is dysregulated by the P2X7 receptor in the SOD1-G93A microglia model of amyotrophic lateral sclerosis. J. Immunol. 190, 5187-5195. 10.4049/jimmunol.1203262</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1203262</ArticleId><ArticleId IdType="pubmed">23589615</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S., Amadio S., Parisi C., Matteucci A., Potenza R. L., Armida M., Popoli P., D'ambrosi N. and Volonte C. (2014). Spinal cord pathology is ameliorated by P2X7 antagonism in a SOD1-mutant mouse model of amyotrophic lateral sclerosis. Dis. Model. Mech. 7, 1101-1109. 10.1242/dmm.017038</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.017038</ArticleId><ArticleId IdType="pmc">PMC4142730</ArticleId><ArticleId IdType="pubmed">25038061</ArticleId></ArticleIdList></Reference><Reference><Citation>Bame M., Pentiak P. A., Needleman R. and Brusilow W. S. A. (2012). Effect of sex on lifespan, disease progression, and the response to methionine sulfoximine in the SOD1 G93A mouse model for ALS. Gend. Med. 9, 524-535. 10.1016/j.genm.2012.10.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genm.2012.10.014</ArticleId><ArticleId IdType="pubmed">23217569</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartlett R., Sluyter V., Watson D., Sluyter R. and Yerbury J. J. (2017). P2X7 antagonism using Brilliant Blue G reduces body weight loss and prolongs survival in female SOD1G93A amyotrophic lateral sclerosis mice. PeerJ 5, e3064 10.7717/peerj.3064</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.3064</ArticleId><ArticleId IdType="pmc">PMC5335685</ArticleId><ArticleId IdType="pubmed">28265522</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya A., Wang Q., Ao H., Shoblock J. R., Lord B., Aluisio L., Fraser I., Nepomuceno D., Neff R. A., Welty N. et al. (2013). Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br. J. Pharmacol. 170, 624-640. 10.1111/bph.12314</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.12314</ArticleId><ArticleId IdType="pmc">PMC3792000</ArticleId><ArticleId IdType="pubmed">23889535</ArticleId></ArticleIdList></Reference><Reference><Citation>Bo X., Jiang L.-H., Wilson H. L., Kim M., Burnstock G., Surprenant A. and North R. A. (2003). Pharmacological and biophysical properties of the human P2X5 receptor. Mol. Pharmacol. 63, 1407-1416. 10.1124/mol.63.6.1407</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.63.6.1407</ArticleId><ArticleId IdType="pubmed">12761352</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonafede R. and Mariotti R. (2017). ALS pathogenesis and therapeutic approaches: the role of mesenchymal stem cells and extracellular vesicles. Front. Cell. Neurosci. 11, 80 10.3389/fncel.2017.00080</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2017.00080</ArticleId><ArticleId IdType="pmc">PMC5359305</ArticleId><ArticleId IdType="pubmed">28377696</ArticleId></ArticleIdList></Reference><Reference><Citation>Brites D. and Vaz A. R. (2014). Microglia centered pathogenesis in ALS: insights in cell interconnectivity. Front. Cell. Neurosci. 8, 117 10.3389/fncel.2014.00117</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00117</ArticleId><ArticleId IdType="pmc">PMC4033073</ArticleId><ArticleId IdType="pubmed">24904276</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A. C., Manzano R., Mendon&#xe7;a D. M. F., Mu&#xf1;oz M.&#xad;J., Zaragoza P. and Osta R. (2014). Amyotrophic lateral sclerosis: a focus on disease progression. Biomed Res. Int. 2014, 925101 10.1155/2014/925101</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/925101</ArticleId><ArticleId IdType="pmc">PMC4137497</ArticleId><ArticleId IdType="pubmed">25157374</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervetto C., Frattaroli D., Maura G. and Marcoli M. (2013). Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism. Toxicology 311, 69-77. 10.1016/j.tox.2013.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tox.2013.04.004</ArticleId><ArticleId IdType="pubmed">23583883</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P., Tauber C., Vercoullie J., Arlicot N., Prunier C., Praline J., Nicolas G., Venel Y., Hommet C., Baulieu J.-L. et al. (2012). Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS ONE 7, e52941 10.1371/journal.pone.0052941</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052941</ArticleId><ArticleId IdType="pmc">PMC3534121</ArticleId><ArticleId IdType="pubmed">23300829</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz M. P. (2018). Edaravone (Radicava): a novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis. P. T. 43, 25-28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5737249</ArticleId><ArticleId IdType="pubmed">29290672</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis M. J., Alexander S., Cirino G., Docherty J. R., George C. H., Giembycz M. A., Hoyer D., Insel P. A., Izzo A. A., Ji Y. et al. (2018). Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers. Br. J. Pharmacol. 175, 987-993. 10.1111/bph.14153</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14153</ArticleId><ArticleId IdType="pmc">PMC5843711</ArticleId><ArticleId IdType="pubmed">29520785</ArticleId></ArticleIdList></Reference><Reference><Citation>Disabato D. J., Quan N. and Godbout J. P. (2016). Neuroinflammation: the devil is in the details. J. Neurochem. 139 Suppl. 2, 136-153. 10.1111/jnc.13607</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13607</ArticleId><ArticleId IdType="pmc">PMC5025335</ArticleId><ArticleId IdType="pubmed">26990767</ArticleId></ArticleIdList></Reference><Reference><Citation>Doble A. (1996). The pharmacology and mechanism of action of riluzole. Neurology 47, S233-S241. 10.1212/WNL.47.6_Suppl_4.233S</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.47.6_Suppl_4.233S</ArticleId><ArticleId IdType="pubmed">8959995</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabbrizio P., Amadio S., Apolloni S. and Volont&#xe9; C. (2017). P2X7 receptor activation modulates autophagy in SOD1-G93A mouse microglia. Front. Cell. Neurosci. 11, 249 10.3389/fncel.2017.00249</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2017.00249</ArticleId><ArticleId IdType="pmc">PMC5566572</ArticleId><ArticleId IdType="pubmed">28871219</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabbrizio P., Apolloni S., Bianchi A., Salvatori I., Valle C., Lanzuolo C., Bendotti C., Nardo G. and Volont&#xe9; C. (2020). P2X7 activation enhances skeletal muscle metabolism and regeneration in SOD1G93A mouse model of amyotrophic lateral sclerosis. Brain Pathol. 30, 272-282. 10.1111/bpa.12774</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12774</ArticleId><ArticleId IdType="pmc">PMC7065186</ArticleId><ArticleId IdType="pubmed">31376190</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandelman M., Peluffo H., Beckman J. S., Cassina P. and Barbeito L. (2010). Extracellular ATP and the P2X7 receptor in astrocyte-mediated motor neuron death: implications for amyotrophic lateral sclerosis. J. Neuroinflammation 7, 33 10.1186/1742-2094-7-33</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-7-33</ArticleId><ArticleId IdType="pmc">PMC2901222</ArticleId><ArticleId IdType="pubmed">20534165</ArticleId></ArticleIdList></Reference><Reference><Citation>Gundersen H. J. G., Jensen E. B. V., Kieu K. and Nielsen J. (1999). The efficiency of systematic sampling in stereology&#x2014;reconsidered. J. Microsc. 193, 199-211. 10.1046/j.1365-2818.1999.00457.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2818.1999.00457.x</ArticleId><ArticleId IdType="pubmed">10348656</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M., Pu H., Chiu A., Dal Canto M., Polchow C., Alexander D., Caliendo J., Hentati A., Kwon Y., Deng H. et al. (1994). Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264, 1772-1775. 10.1126/science.8209258</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O., Al-Chalabi A., Chio A., Corr E. M., Logroscino G., Robberecht W., Shaw P. J., Simmons Z. and Van Den Berg L. H. (2017). Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers 3, 17085 10.1038/nrdp.2017.85</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.85</ArticleId><ArticleId IdType="pubmed">29052611</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison M., O'Brien A., Adams L., Cowin G., Ruitenberg M. J., Sengul G. and Watson C. (2013). Vertebral landmarks for the identification of spinal cord segments in the mouse. Neuroimage 68, 22-29. 10.1016/j.neuroimage.2012.11.048</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2012.11.048</ArticleId><ArticleId IdType="pubmed">23246856</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzipetros T., Kidd J. D., Moreno A. J., Thompson K., Gill A. and Vieira F. G. (2015). A quick phenotypic neurological scoring system for evaluating disease progression in the SOD1-G93A mouse model of ALS. J. Vis. Exp., 104, 53257 10.3791/53257</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/53257</ArticleId><ArticleId IdType="pmc">PMC4692639</ArticleId><ArticleId IdType="pubmed">26485052</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez-Pacheco A., Diaz-Hernandez M., Arribas-Bl&#xe1;zquez M., Sanz-Rodriguez A., Olivos-Or&#xe9; L. A., Artalejo A. R., Alves M., Letavic M., Miras-Portugal M. T., Conroy R. M. et al. (2016). Transient P2X7 receptor antagonism produces lasting reductions in spontaneous seizures and gliosis in experimental temporal lobe epilepsy. J. Neurosci. 36, 5920-5932. 10.1523/JNEUROSCI.4009-15.2016</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4009-15.2016</ArticleId><ArticleId IdType="pmc">PMC6601816</ArticleId><ArticleId IdType="pubmed">27251615</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo S. and Bean B. P. (2011). Inhibition of neuronal voltage-gated sodium channels by brilliant blue G. Mol. Pharmacol. 80, 247-257. 10.1124/mol.110.070276</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.110.070276</ArticleId><ArticleId IdType="pmc">PMC3141889</ArticleId><ArticleId IdType="pubmed">21536754</ArticleId></ArticleIdList></Reference><Reference><Citation>Karasawa A. and Kawate T. (2016). Structural basis for subtype-specific inhibition of the P2X7 receptor. eLife 5, e22153 10.7554/elife.22153</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/elife.22153</ArticleId><ArticleId IdType="pmc">PMC5176352</ArticleId><ArticleId IdType="pubmed">27935479</ArticleId></ArticleIdList></Reference><Reference><Citation>Leitner M., Menzies S. and Lutz C. (2009). Working with ALS mice: guidelines for preclinical testing &amp; colony management. Jackson Lab.</Citation></Reference><Reference><Citation>Liu Y., Pattamatta A., Zu T., Reid T., Bardhi O., Borchelt D. R., Yachnis A. T. and Ranum L. P. W. (2016). C9orf72 BAC mouse model with motor deficits and neurodegenerative features of ALS/FTD. Neuron 90, 521-534. 10.1016/j.neuron.2016.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.005</ArticleId><ArticleId IdType="pubmed">27112499</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A. C., Bendotti C., Blaugrund E., Chio A., Greensmith L., Loeffler J.-P., Mead R., Niessen H. G., Petri S., Pradat P.-F. et al. (2010). Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph. Lateral Scler. 11, 38-45. 10.3109/17482960903545334</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903545334</ArticleId><ArticleId IdType="pubmed">20184514</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutz C. (2018). Mouse models of ALS: past, present and future. Brain Res. 1693, 1-10. 10.1016/j.brainres.2018.03.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.03.024</ArticleId><ArticleId IdType="pubmed">29577886</ArticleId></ArticleIdList></Reference><Reference><Citation>Ly D., Dongol A., Cuthbertson P., Guy T. V., Geraghty N. J., Sophocleous R. A., Sin L., Turner B. J., Watson D., Yerbury J. J. et al. (2020). The P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1 G93A mice. Purinergic Signal. 16, 109-122. 10.1007/s11302-020-09692-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11302-020-09692-4</ArticleId><ArticleId IdType="pmc">PMC7166237</ArticleId><ArticleId IdType="pubmed">32170537</ArticleId></ArticleIdList></Reference><Reference><Citation>Miana-Mena F. J., Mu&#xf1;oz M. J., Yag&#xfc;e G., Mendez M., Moreno M., Ciriza J., Zaragoza P. and Osta R. (2005). Optimal methods to characterize the G93A mouse model of ALS. Amyotroph. Lateral Scler. 6, 55-62. 10.1080/14660820510026162</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820510026162</ArticleId><ArticleId IdType="pubmed">16036427</ArticleId></ArticleIdList></Reference><Reference><Citation>Parisi C., Napoli G., Pelegrin P. and Volont&#xe9; C. (2016). M1 and M2 functional imprinting of primary microglia: role of P2X7 activation and miR-125b. Mediators Inflamm. 2016, 2989548 10.1155/2016/2989548</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/2989548</ArticleId><ArticleId IdType="pmc">PMC5206439</ArticleId><ArticleId IdType="pubmed">28090150</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfohl S. R., Halicek M. T. and Mitchell C. S. (2015). Characterization of the contribution of genetic background and gender to disease progression in the SOD1 G93A mouse model of amyotrophic lateral sclerosis: a meta-analysis. J. Neuromuscul. Dis. 2, 137-150. 10.3233/JND-140068</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JND-140068</ArticleId><ArticleId IdType="pmc">PMC4652798</ArticleId><ArticleId IdType="pubmed">26594635</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T. and Rothstein J. D. (2015). Rodent models of amyotrophic lateral sclerosis. Curr. Protoc. Pharmacol. 69, 5.67.1-5.67.21. 10.1002/0471141755.ph0567s69</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471141755.ph0567s69</ArticleId><ArticleId IdType="pmc">PMC4562058</ArticleId><ArticleId IdType="pubmed">26344214</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu F. and Dahl G. (2009). A permeant regulating its permeation pore: inhibition of pannexin 1 channels by ATP. Am. J. Physiol. Cell Physiol. 296, C250-C255. 10.1152/ajpcell.00433.2008</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00433.2008</ArticleId><ArticleId IdType="pmc">PMC2643853</ArticleId><ArticleId IdType="pubmed">18945939</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyffert C., Schmalzing G. and Markwardt F. (2004). Dissecting individual current components of co-expressed human P2X1 and P2X7 receptors. Curr. Top. Med. Chem. 4, 1719-1730. 10.2174/1568026043387160</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026043387160</ArticleId><ArticleId IdType="pubmed">15579104</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson K. V., Deng M. and Ting J. P.-Y. (2019). The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 19, 477-489. 10.1038/s41577-019-0165-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0165-0</ArticleId><ArticleId IdType="pmc">PMC7807242</ArticleId><ArticleId IdType="pubmed">31036962</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y. and Le W. (2016). Differential Roles of M1 and M2 microglia in neurodegenerative diseases. Mol. Neurobiol. 53, 1181-1194. 10.1007/s12035-014-9070-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-014-9070-5</ArticleId><ArticleId IdType="pubmed">25598354</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang L., Ma Y., Liu X.-L., Chen L. and Fan D.-S. (2019). Better survival in female SOD1-mutant patients with ALS: a study of SOD1-related natural history. Transl. Neurodegener. 8, 2 10.1186/s40035-018-0142-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-018-0142-8</ArticleId><ArticleId IdType="pmc">PMC6325854</ArticleId><ArticleId IdType="pubmed">30637102</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker D. G. and Lue L.-F. (2015). Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains. Alzheimers Res. Ther. 7, 56 10.1186/s13195-015-0139-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-015-0139-9</ArticleId><ArticleId IdType="pmc">PMC4543480</ArticleId><ArticleId IdType="pubmed">26286145</ArticleId></ArticleIdList></Reference><Reference><Citation>West M. J., Slomianka L. and Gundersen H. J. G. (1991). Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat. Rec. 231, 482-497. 10.1002/ar.1092310411</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ar.1092310411</ArticleId><ArticleId IdType="pubmed">1793176</ArticleId></ArticleIdList></Reference><Reference><Citation>White M. A., Kim E., Duffy A., Adalbert R., Phillips B. U., Peters O. M., Stephenson J., Yang S., Massenzio F., Lin Z. et al. (2018). TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat. Neurosci. 21, 552-563. 10.1038/s41593-018-0113-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0113-5</ArticleId><ArticleId IdType="pmc">PMC5884423</ArticleId><ArticleId IdType="pubmed">29556029</ArticleId></ArticleIdList></Reference><Reference><Citation>Wooley C. M., Sher R. B., Kale A., Frankel W. N., Cox G. A. and Seburn K. L. (2005). Gait analysis detects early changes in transgenic SOD1(G93A) mice. Muscle Nerve 32, 43-50. 10.1002/mus.20228</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.20228</ArticleId><ArticleId IdType="pmc">PMC1350398</ArticleId><ArticleId IdType="pubmed">15880561</ArticleId></ArticleIdList></Reference><Reference><Citation>Yiangou Y., Facer P., Durrenberger P., Chessell I. P., Naylor A., Bountra C., Banati R. R. and Anand P. (2006). COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 6, 12 10.1186/1471-2377-6-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-6-12</ArticleId><ArticleId IdType="pmc">PMC1413551</ArticleId><ArticleId IdType="pubmed">16512913</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>